Table 3. Summary of studies on PTL and surgical outcomes after CRS plus HIPEC for peritoneal metastases from CRC.
| Year | Reference | Study type | Study period | Number of patients | Survival analysis for RCC versus LCC |
|---|---|---|---|---|---|
| 2019 | Kelly et al. (48) | Retrospective (Three centers) |
1992-2016 | 115 | Inferior in DFS (HR 2.27, 95% CI 1.09-4.76), inferior in OS (HR 2.57, 95% CI 1.13-5.84) |
| 2019 | Kotha et al. (47) | Retrospective (12 centers) |
2000-2017 | 336 | Inferior in DFS (HR 1.75, 95% CI 1.19-2.56), inferior in OS (HR 1.72, 95% CI 1.09-2.73) |
| 2019 | Péron et al. (46) | Retrospective (16 centers) |
2004-2017 | 796 | No difference in PFS (HR 1.02, 95% CI 0.85-1.23) and OS (HR 0.99, 95% CI 0.79-1.23). |
| 2020 | Blakely et al. (49) | Retrospective (CCR) |
2004-2012 | 272 | Inferior in DFS (median 21 versus 41 months, P = 0.0011) Inferior in OS (median 15.5 versus 34 months, P = 0.0010) |
| 2020 | de Boer et al. (45) | Retrospective (Population-based) |
1995-2016 | 564 | No difference in OS (median 30.3 versus 34.6 months, P = 0.301) |
CCR, California Cancer Registry; CI, confidence interval; CRC, colorectal cancer; CRS, complete cytoreductive surgery; DFS, disease free survival; HIPEC, hyperthermic intraperitoneal chemotherapy; HR, hazard ratio; LCC, left-sided colon cancer; OS, overall survival; PFS, progression free survival; PTL, primary tumor location; RCC, right-sided colon cancer.